<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970056</url>
  </required_header>
  <id_info>
    <org_study_id>PRECEDE</org_study_id>
    <nct_id>NCT04970056</nct_id>
  </id_info>
  <brief_title>Pancreatic Cancer Early Detection Consortium</brief_title>
  <acronym>PRECEDE</acronym>
  <official_title>Pancreatic Cancer Early Detection Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Research Collaborative for Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Research Collaborative for Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct&#xD;
      research on multiple aspects of early detection and prevention of pancreatic ductal&#xD;
      adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history&#xD;
      of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in&#xD;
      genes linked to PDAC risk for longitudinal follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the PRECEDE Consortium is to build a shared resource to drive research&#xD;
      in critical areas necessary for early detection and prevention of PDAC.&#xD;
&#xD;
      The PRECEDE Consortium is an observational prospective cohort study, with single or serial&#xD;
      biosample collection (every 6-12 months) in defined high-risk groups.&#xD;
&#xD;
      A standardized procedure for collection and processing of human blood for the PRECEDE&#xD;
      Consortium will be applied to all blood samples collected as part of the study. Barcoded&#xD;
      samples will be stored at the clinical centers, using the specific labels for the PRECEDE&#xD;
      study and corresponding data will be entered into the study database.&#xD;
&#xD;
      Clinical data and outcomes will be obtained from institutional databases or clinical records&#xD;
      to correlate patient information with laboratory results from biospecimens obtained for&#xD;
      research. Patients will be followed by their attending physician and receive the standard&#xD;
      follow-up care after the procedure in which biospecimen was obtained. It is the intent that&#xD;
      biospecimens will be made available to all consortium investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of PDAC</measure>
    <time_frame>Through study completion, an average of 6 years</time_frame>
    <description>Diagnosis of PDAC</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreas Cyst</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Individuals without history of PDAC meeting any of the following criteria:&#xD;
2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.&#xD;
2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family&#xD;
BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family&#xD;
Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+&#xD;
Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+&#xD;
Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Individuals without history of PDAC meeting any of the following criteria:&#xD;
ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+&#xD;
2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family&#xD;
1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>Individuals without history of PDAC presenting for evaluation who do not meet any criteria above after collection of full family history and/or germline testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>Individuals who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4 and individuals with personal history of PDAC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <description>Individuals with pancreatic cyst(s), that are ineligible for Cohorts 1-5.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A standardized procedure for collection and processing of human blood will be applied to all&#xD;
      blood samples collected as part of the study. Barcoded samples will be stored at the clinical&#xD;
      centers, and corresponding data will be entered into the study database. Any protocol&#xD;
      deviations should also be recorded by each center.&#xD;
&#xD;
      60mL of blood is collected at baseline, 120mL annually, and 60mL at other events.&#xD;
&#xD;
      Eligible individuals who are not seen in person for a clinic visit, who express interest in&#xD;
      enrollment after initial contact, will be sent a copy of the IC document and a saliva&#xD;
      collection kit by mail. Individuals in Cohort 5 may alternatively submit saliva or buccal&#xD;
      swab samples without a clinic visit. Participants will return the signed consent and saliva&#xD;
      sample.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will accrue subjects who present for risk assessment at one of the participating&#xD;
        sites based on history of:&#xD;
&#xD;
          -  one or more family members with PDAC&#xD;
&#xD;
          -  a pathogenic or likely pathogenic germline variant in a gene linked to PDAC risk&#xD;
&#xD;
          -  personal history of PDAC with PGV in genes of research interest and/or part of a&#xD;
             Familial Pancreatic Cancer kindred&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals from the following groups who present for clinical evaluation and&#xD;
             assessment of PDAC risk at any of the participating sites can be offered participation&#xD;
             in the PRECEDE database:&#xD;
&#xD;
        Cohort 1&#xD;
&#xD;
        Individuals without history of PDAC meeting any of the following criteria:&#xD;
&#xD;
          1. 2+ relatives with PDAC on same side of family where 2 affected are first degree&#xD;
             related to each other and at least 1 affected is first degree related to subject; age&#xD;
             50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.&#xD;
&#xD;
          2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest&#xD;
             PDAC in family 3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic&#xD;
             or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+&#xD;
             or 10 years younger than earliest PDAC in family&#xD;
&#xD;
        4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely&#xD;
        pathogenic CDKN2A variant; age 40+ 5. Peutz-Jegher syndrome with STK11 pathogenic or likely&#xD;
        pathogenic variant; age 35+ 6. Hereditary pancreatitis with PRSS1 pathogenic or likely&#xD;
        pathogenic variant and history of pancreatitis; age 40+&#xD;
&#xD;
        Cohort 2&#xD;
&#xD;
        Individuals without history of PDAC meeting any of the following criteria:&#xD;
&#xD;
          1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of&#xD;
             family history, age 50+&#xD;
&#xD;
          2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting&#xD;
             other criteria above; age 50+ or 10 years younger than earliest PDAC in family&#xD;
&#xD;
          3. 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family&#xD;
             member&#xD;
&#xD;
        Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to&#xD;
        qualify for Cohorts 1 or 2)&#xD;
&#xD;
        Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any&#xD;
        criteria above after collection of full family history and/or germline testing&#xD;
&#xD;
        Cohort 5 Individuals who are not otherwise engaged in pancreas surveillance at a&#xD;
        participating site may be invited to participate in the PRECEDE database and to donate a&#xD;
        biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include&#xD;
        relatives of individuals in Cohorts 1-4 and individuals with personal history of PDAC.&#xD;
&#xD;
        Cohort 6 Individuals with pancreatic cyst(s), that are ineligible for Cohorts 1-5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals not meeting the criteria above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Simeone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Fava, MPA</last_name>
    <phone>7346654108</phone>
    <email>melissa.fava@arborresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Graff, PhD</last_name>
    <phone>7346654108</phone>
    <email>john.graff@arborresearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Sarno</last_name>
      <email>stsarno@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Andy Lowy</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joy Liau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liliana Bancila</last_name>
      <email>Liliana.Bancila@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Srinivas Gaddam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Merenda</last_name>
      <email>scott.merenda@yale.edu</email>
    </contact>
    <investigator>
      <last_name>James Farrell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Pradieu</last_name>
      <email>Pradieu.Guillermo@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Yan Bi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Wallace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Cortizas</last_name>
      <email>ecortizas@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Sussman</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nipun Merchant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Chisolm</last_name>
      <email>Abigail.Chisholm@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jenny Permuth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Eilers</last_name>
      <email>zeilers@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonia Kupfer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ava Siegel</last_name>
      <email>ASIEGEL2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Gregoire</last_name>
      <email>Cara.Gregoire@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>James Lindberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Volk</last_name>
      <email>stomanic@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elena Stoffel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rich Kwon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hoy</last_name>
      <email>christina.hoy@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kelsey Klute</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Everett</last_name>
      <email>Jessica.Everett@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Chun Kim</last_name>
      <email>Jennifer.ChunKim@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Simeone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine At Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Aronson</last_name>
      <email>anne.aronson@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Aimee Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanjina Razzaque</last_name>
      <email>tr2432@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>FAy Kastrinos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Bittner</last_name>
      <email>Krystle_Bittner@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Darren Carpizo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Kaul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dove Keith</last_name>
      <email>keithd@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Grossberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brett Sheppard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Heiman</last_name>
      <email>Jordan.Heiman@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Bryson Katona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (Upmc)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Dudley</last_name>
      <email>dudleyre@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Randy Brand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seyda Baydogan</last_name>
      <email>SBaydogan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Florencia McAllister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Anson</last_name>
      <email>Jo.Anson@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Cathryn Koptiuch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Ann Lai</last_name>
      <email>LLai@medicine.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Teri Brentnall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Cremon</last_name>
      <email>ccremin@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Intan Schrader</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uhn Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Spring Holter</last_name>
      <email>Spring.Holter@sinaihealthsystem.ca</email>
    </contact>
    <investigator>
      <last_name>Steven Gallinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Haigh</last_name>
      <email>crystal.haigh@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>George Zogopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Raitses</last_name>
      <email>Maria.RaitsesGurevich@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Talia Golan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Paiella</last_name>
      <email>salvatore.paiella@univr.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Paiella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramón y Cajal University Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marien Castillo-Sanchez</last_name>
      <email>marienz707.cs@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Julie Earl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Cyst</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

